Ask AI
Hemostatic Rebalancing in Hemophilia

CE / CME

Clinical Focus in Hemophilia: Integrating Hemostatic Rebalancing Therapies Into Personalized, Evidence-Based Patient Care

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: March 16, 2026

Expiration: September 15, 2026

Activity

Progress
1 2 3
Course Completed

References

  1. Chowdary P, Carcao M, Kenet G, et al. Haemophilia. Lancet. 2025;405:736-750.
  2. Hemophilia Symptoms. hemophilianewstoday.com/symptoms-hemophilia. Accessed March 10, 2026.
  3. Wilkins RA, Stephensen D, Siddle H, et al. Twelve-month prevalence of haemarthrosis and joint disease using the Haemophilia Joint Health score: evaluation of the UK National Haemophilia Database and Haemtrack patient reported data: an observational study. BMJ Open. 2022;12:e052358.
  4. Astermark J, Blatný J, Königs C, et al. Considerations for shared decision management in previously untreated patients with hemophilia A or B. Ther Adv Hematol. 2023:14:20406207231165857.
  5. Kurnik K, Bidlingmaier C, Olivieri M. How do I counsel parents of a newly diagnosed boy with haemophilia A? Hamostaseologie. 2020;40:88-96.
  6. O’Hara S, Castro F, Black J, et al. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. Haemophilia. 2021;27:113-119.
  7. Philipp C. The aging patient with hemophilia: complications, comorbidities, and management issues. Hematology Am Soc Hematol Educ Program. 2010;2010:191-6.
  8. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl. 6):1-15
  9. Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133:389-398.
  10. Chai-Adisaksopha C, Noone D, Curtis R, et al. Non-severe haemophilia: Is it benign? Insights from the PROBE study. Haemophilia. 2021;27(Suppl. 1):17-24.
  11. Osooli M, Lövdahl S, Carlsson KS, et al. Comparative burden of arthropathy in mild haemophilia: a register-based study in Sweden. Haemophilia. 2017;23:e79-e86.
  12. Manco-Johnson M, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535-544.
  13. Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Adv. 2020;4:2541-2459.
  14. Maneikis K, Krumb E, Hermans C. Normalization in hemophilia: conceptual foundations and clinical implications. Res Pract Thromb Haemost. 2025;9:103200.
  15. Young G, Kavakli K, Klamroth R, et al. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 2025;145:2966-2977.
  16. Fitusiran [prescribing information]. Cambridge, MA: Genzyme Corporation; 2025.
  17. Young G, Lenting PJ, Croteau SF, et al. Antithrombin lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost. 2023;7:100179.
  18. Concizumab [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; July 2025.
  19. Windyga J, Apte S, Astermark J, et al. Efficacy and safety of concizumab prophylaxis in haemophilia A or B with and without inhibitors: 56-week cut-off results of the phase 3 explorer7 and explorer8 studies. Presented at: 17th Annual Congress of the European Association for Haemophilia and Allied Disorders. Abstr OR07.
  20. Seremetis SV, Cepo K, Rasmussen JS, et al. Risk mitigation strategy for concizumab clinical trials after pause due to non-fatal thrombotic events. Blood. 2020:136 (suppl 1):40.
  21. Matsushita T, Shapiro A, Abraham A, et al. Phase 3 trial of concizumab in hemophilia with inhibitors. N Engl J Med. 2023;389:783-794.
  22. Mahlangu J, Castaman G, Abraham A, et al. Management of breakthrough bleeding episodes in the phase 3 concizumab studies. Presented at: International Society on Thrombosis and Haemostasis 2024 Congress. Abstr OC 40.5.
  23. Marstacimab [prescribing information]. New York, NY: Pfizer Inc; 2025.
  24. Matino D, Acharya SS, Taylor CT, et al. Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. Blood. 2026;147:920-931.
  25. Matino D, Palladino A, Taylor CT, et al. Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial. Blood. 2025;146:1654-1663.